WAY-151932
Based on 1 Customer Validation
WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 220460-92-4
- Formula: C23H19ClN4O
- Molecular Weight:402.88
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Clinical Compound Library
HY-L026
-
Endocrinology Compound Library
HY-L047
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
All Vasopressin Receptor Isoforms
More
Biological Activity
IC50: 80.3 nM (human-V2 binding), 778 nM (human-V1a binding)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
125 nM
Compound: 3, WAY-VNA-932
|
Activity at human oxytocin receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
Activity at human oxytocin receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
|
[PMID: 20104850] |
| CHO | EC50 |
39.9 nM
Compound: 3, WAY-VNA-932
|
Activity at human vasopressin V2 receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
Activity at human vasopressin V2 receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
|
[PMID: 20104850] |
| CHO | EC50 |
465 nM
Compound: 3, WAY-VNA-932
|
Activity at human vasopressin V1a receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
Activity at human vasopressin V1a receptor expressed in CHO cells by NFAT-luciferase gene reporter assay
|
[PMID: 20104850] |
| CHO | IC50 |
353 nM
Compound: 1
|
Displacement of [3H]oxytocin from human oxytocin receptor expressed in CHO cells
Displacement of [3H]oxytocin from human oxytocin receptor expressed in CHO cells
|
[PMID: 17855087] |
| CHO | IC50 |
778 nM
Compound: 1
|
Displacement of [3H]manning ligand from human vasopressin V1a receptor expressed in CHO cells
Displacement of [3H]manning ligand from human vasopressin V1a receptor expressed in CHO cells
|
[PMID: 17855087] |
| CHO | IC50 |
778 nM
Compound: VNA-932
|
Displacement of [3H]AVP from human V1a receptor expressed in CHO cells
Displacement of [3H]AVP from human V1a receptor expressed in CHO cells
|
[PMID: 16297621] |
| HEK293 | EC50 |
<1 nM
Compound: 2, VAN-932
|
Agonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as increase in intracellular cAMP level by CRE-luciferase reporter gene assay
Agonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as increase in intracellular cAMP level by CRE-luciferase reporter gene assay
|
[PMID: 19053774] |
WAY-151932 (VNA-932) stimulates cAMP formation in LV2 cells expressing the hV2 receptors in a dose-dependent manner with an EC50 of 0.74±0.07 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 220460-92-4
-
Appearance Solid
-
Molecular Weight 402.88
-
Formula C23H19ClN4O
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(N2N=C(C)C=C2)C=C1Cl)N3CC4=CC=CN4CC5=CC=CC=C53
-
Synonyms
VNA-932; WAY-VNA 932
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 200 mg/mL (496.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (12.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (12.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Molinari AJ, et al. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5796-800. [Content Brief]
[2]. Failli AA, et al. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4821 mL | 12.4106 mL | 24.8213 mL | 62.0532 mL |
| 5 mM | 0.4964 mL | 2.4821 mL | 4.9643 mL | 12.4106 mL | |
| 10 mM | 0.2482 mL | 1.2411 mL | 2.4821 mL | 6.2053 mL | |
| 15 mM | 0.1655 mL | 0.8274 mL | 1.6548 mL | 4.1369 mL | |
| 20 mM | 0.1241 mL | 0.6205 mL | 1.2411 mL | 3.1027 mL | |
| 25 mM | 0.0993 mL | 0.4964 mL | 0.9929 mL | 2.4821 mL | |
| 30 mM | 0.0827 mL | 0.4137 mL | 0.8274 mL | 2.0684 mL | |
| 40 mM | 0.0621 mL | 0.3103 mL | 0.6205 mL | 1.5513 mL | |
| 50 mM | 0.0496 mL | 0.2482 mL | 0.4964 mL | 1.2411 mL | |
| 60 mM | 0.0414 mL | 0.2068 mL | 0.4137 mL | 1.0342 mL | |
| 80 mM | 0.0310 mL | 0.1551 mL | 0.3103 mL | 0.7757 mL | |
| 100 mM | 0.0248 mL | 0.1241 mL | 0.2482 mL | 0.6205 mL |
WAY-151932 Related Classifications
HY-19381 Related Classifications
Powered by Bioz